Media Coverage

Aratana gains positive results for cat pain candidate


Jul 26, 2017 - Animal Pharm

By Joseph Harvey
Animal Pharm
July 26, 2017 

The Kansas-based firm gained the results under an FDA-concurred protocol, as it aims to develop a version of its Nocita product – approved for dogs in the US – for the feline market.

Aratana said the study in client-owned cats undergoing an elective onychectomy showed "bupivacaine liposome injectable suspension met protocol-defined efficacy success criteria, which were statistically significant (p < 0.05)".

In June, the firm submitted results from the pivotal safety study to the US FDA's Center for Veterinary Medicine for AT-003 in cats. Aratana will use data from both of these studies to support an application for approval of the therapeutic in cats.

Bupivacaine liposome injectable suspension also features in Nocita, which received US approvallast year as a local post-operative analgesic for cranial cruciate ligament surgery in dogs.

Nocita is a long-acting anesthetic designed to last up to 72 hours post-surgery by releasing bupivacaine over time from multi-vesicular liposomes deposited in the tissue. It is administered as a single dose by tissue infiltration during closure of cranial cruciate ligament surgery in dogs.

While Aratana is focusing on bringing 'Nocita for cats' to market in the US, it will aim to bring Nocita to dogs outside the States in 2018.

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum